What is Immunome's stock issuance proceeds?

Immunome (IMNM) reported stock issuance proceeds of $229K in Q1 2026.

How has Immunome's stock issuance proceeds changed year-over-year?

Immunome's stock issuance proceeds increased by 7.5% year-over-year, from $213K to $229K.

What is the long-term trend for Immunome's stock issuance proceeds?

Over 2 years (2021 to 2025), Immunome's stock issuance proceeds has grown at a 3.3% compound annual growth rate (CAGR), from $43.04M to $45.9M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Immunome IMNM Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Arcus BiosciencesRCUS

$0-100%

Nuvation BioNUVB

$908K-16.1%

SELLAS Life Sciences Group, Inc.SLS

$66K+37.5%

ArriVent BioPharma, Inc.AVBP

$54.72M+740%

IDEAYA Biosciences, Inc.IDYA

$1.19M+4.9%

ImmunityBio, Inc.IBRX

$971K+341%

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's stock issuance proceeds?: Immunome (IMNM) reported stock issuance proceeds of $229K in Q1 2026.
How has Immunome's stock issuance proceeds changed year-over-year?: Immunome's stock issuance proceeds increased by 7.5% year-over-year, from $213K to $229K.
What is the long-term trend for Immunome's stock issuance proceeds?: Over 2 years (2021 to 2025), Immunome's stock issuance proceeds has grown at a 3.3% compound annual growth rate (CAGR), from $43.04M to $45.9M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.